These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23833414)

  • 1. Selective doxorubicin drug eluting beads chemoembolization of hypovascular hepatocellular carcinoma using cone beam computed tomography.
    Kalra N; Mahajan D; Chawla Y; Khandelwal N
    Indian J Radiol Imaging; 2012 Oct; 22(4):254-6. PubMed ID: 23833414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cone-Beam Computed Tomography-Based Spatial Prediction of Drug Dose After Transarterial Chemoembolization Using Radiopaque Drug-Eluting Beads in Woodchuck Hepatocellular Carcinoma.
    Mikhail AS; Pritchard WF; Negussie AH; Inkiyad G; Long DJ; Mauda-Havakuk M; Wakim PG; van der Sterren W; Levy EB; Lewis AL; Karanian JW; Wood BJ
    Invest Radiol; 2022 Aug; 57(8):495-501. PubMed ID: 35239613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.
    Maschke SK; Werncke T; Klöckner R; Rodt T; Renne J; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
    Abdom Radiol (NY); 2018 May; 43(5):1245-1253. PubMed ID: 28840307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?
    Loffroy R; Lin M; Yenokyan G; Rao PP; Bhagat N; Noordhoek N; Radaelli A; Blijd J; Liapi E; Geschwind JF
    Radiology; 2013 Feb; 266(2):636-48. PubMed ID: 23143027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone.
    Peisen F; Maurer M; Grosse U; Nikolaou K; Syha R; Artzner C; Bitzer M; Horger M; Grözinger G
    Eur J Radiol; 2021 Jul; 140():109768. PubMed ID: 33991970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE).
    Nakano MM; Yamamoto A; Nishida N; Hamuro M; Hamamoto S; Jogo A; Sohgawa E; Kageyama K; Minami T; Miki Y
    Jpn J Radiol; 2019 Jul; 37(7):543-548. PubMed ID: 31055710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of drug-eluting bead transarterial chemoembolization loaded with cisplatin on normal dogs.
    Nakasumi K; Yamamoto N; Takami T; Itoh H; Itamoto K; Horikirizono H; Iseri T; Nakaichi M; Nemoto Y; Sunahara H; Tani K
    J Vet Med Sci; 2022 Jan; 84(1):114-120. PubMed ID: 34866073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-phase Cone-beam CT-based Navigation Imaging Significantly Enhances Tumor Detectability and Aids Superselective Transarterial Chemoembolization of Liver Cancer.
    Yao X; Yan D; Jiang X; Li X; Zeng H; Liu D; Li H
    Acad Radiol; 2018 Aug; 25(8):1031-1037. PubMed ID: 29398432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.
    Duan F; Wang EQ; Lam MG; Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Kuo WT; Hofmann LV; Sze DY
    Radiology; 2016 Feb; 278(2):612-21. PubMed ID: 26334787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-phase cone-beam computed tomography to see, reach, and treat hepatocellular carcinoma during drug-eluting beads transarterial chemo-embolization.
    Tacher V; Lin M; Bhagat N; Abi Jaoudeh N; Radaelli A; Noordhoek N; Carelsen B; Wood BJ; Geschwind JF
    J Vis Exp; 2013 Dec; (82):50795. PubMed ID: 24326874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety.
    Ballı HT; Aikimbaev K
    Diagn Interv Radiol; 2020 Sep; 26(5):482-487. PubMed ID: 32815520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma.
    Nam HC; Jang B; Song MJ
    World J Gastroenterol; 2016 Oct; 22(40):8853-8861. PubMed ID: 27833376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response.
    Suk Oh J; Jong Chun H; Gil Choi B; Giu Lee H
    J Vasc Interv Radiol; 2013 Apr; 24(4):483-9. PubMed ID: 23452553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
    Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
    Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
    Bi Y; Shi X; Ren J; Yi M; Han X; Song M
    BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber (<100 μm) Beads.
    Chang WC; Hsu HH; Chiu SH; Huang WY; Lo CH; Lin HH; Huang PC; Shih YL; Wan YL
    J Hepatocell Carcinoma; 2021; 8():937-949. PubMed ID: 34422707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.